Literature DB >> 15546207

Irreversible engineering of the multielement-binding antibody 2D12.5 and its complementary ligands.

Todd M Corneillie1, Kelvin C Lee, Paul A Whetstone, Jeremy P Wong, Claude F Meares.   

Abstract

Engineering the permanent formation of a receptor-ligand complex has a number of potential applications in chemistry and biology, including targeted medical imaging and therapy. Starting from the crystal structure of the rare-earth-DOTA binding antibody 2D12.5 (Corneillie, T. M., Fisher, A. J., and Meares, C. F. (2003) J. Am. Chem. Soc. 125, 15039-15048), we used the site-directed incorporation of cysteine nucleophiles at the periphery of the antibody's binding site, paired with the chemical design of a weakly electrophilic ligand, to produce a receptor-ligand pair that associates efficiently and permanently. Protein residues proximal to the ligand's side chain were identified for engineering cysteine mutants. Fab fragments incorporating a cysteine at position 54, 55, or 56 of the heavy chain (complementarity determining region 2) were designed from the structure and then cloned, expressed in Drosophila S2 cells, and tested for reactivity with mildly electrophilic DOTA-yttrium ligands. All showed permanent binding activity, indicating that there is some tolerance for the location of the reactive mutant on the protein surface near the binding site. The G54C Fab mutant displayed the highest expression levels and permanent binding activity in initial experiments and was produced in high yield for further study. Upon examining the behavior of the G54C mutant with a small set of electrophilic ligands, differences in reactivity were observed which indicated that the substituents near the electrophilic atom can be important determinants of permanent binding. The G54C mutant permanently attaches to Y(3+) complexes of (S)-2-(4-acrylamidobenzyl)-DOTA with a half-time of approximately 13 min at 37 degrees C, making it potentially useful for in vivo pretargeting applications.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546207     DOI: 10.1021/bc049824m

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  8 in total

1.  Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation.

Authors:  Bernadette V Marquez; Heather E Beck; Tolulope A Aweda; Brett Phinney; Cynthia Holsclaw; William Jewell; Diana Tran; Jeffrey J Day; Malalage N Peiris; Charles Nwosu; Carlito Lebrilla; Claude F Meares
Journal:  Bioconjug Chem       Date:  2012-05-04       Impact factor: 4.774

2.  New covalent capture probes for imaging and therapy, based on a combination of binding affinity and disulfide bond formation.

Authors:  Tolulope A Aweda; Vahid Eskandari; David L Kukis; David L Boucher; Bernadette V Marquez; Heather E Beck; Gregory S Mitchell; Simon R Cherry; Claude F Meares
Journal:  Bioconjug Chem       Date:  2011-07-22       Impact factor: 4.774

Review 3.  The chemistry of irreversible capture.

Authors:  Claude F Meares
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

4.  Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.

Authors:  Simone Krebs; Afruja Ahad; Lukas M Carter; Justin Eyquem; Christian Brand; Meghan Bell; Vladimir Ponomarev; Thomas Reiner; Claude F Meares; Stephen Gottschalk; Michel Sadelain; Steven M Larson; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2018-06-14       Impact factor: 10.057

5.  Rates and equilibria for probe capture by an antibody with infinite affinity.

Authors:  Tolulope A Aweda; Heather E Beck; Anna M Wu; Liu H Wei; Wolfgang A Weber; Claude F Meares
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

Review 6.  Chemically modified antibodies as diagnostic imaging agents.

Authors:  Jeffrey J Day; Bernadette V Marquez; Heather E Beck; Tolulope A Aweda; Prasad D Gawande; Claude F Meares
Journal:  Curr Opin Chem Biol       Date:  2010-10-15       Impact factor: 8.822

7.  Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.

Authors:  Brian M Zeglis; Christian Brand; Dalya Abdel-Atti; Kathryn E Carnazza; Brendon E Cook; Sean Carlin; Thomas Reiner; Jason S Lewis
Journal:  Mol Pharm       Date:  2015-08-31       Impact factor: 4.939

8.  Cysteinylated protein as reactive disulfide: an alternative route to affinity labeling.

Authors:  Zheng Miao; Mark R McCoy; Diment D Singh; Brianda Barrios; Oliver L Hsu; Sarah M Cheal; Claude F Meares
Journal:  Bioconjug Chem       Date:  2007-12-07       Impact factor: 4.774

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.